Azenta Treats B Medical as Discontinued, Refocuses on Sample Management; Sale Nears Close

Azenta treating B Medical as discontinued as sale nears close

Strategic divestiture reshapes continuing operations

Azenta, the life sciences sample management and multiomics company, is treating B Medical Systems as discontinued operations as it pursues a sale, a move that materially reshapes the composition of its continuing business. The company says it has entered into a definitive agreement following its earlier announcement and expects the sale to close on or before March 31, 2026. By removing B Medical from continuing operations, Azenta narrows its operational focus to its core Sample Management Solutions and Multiomics segments.

Management frames the divestiture as a step to concentrate resources on laboratory automation, sample storage and sequencing-related services that underpin its core platform. The accounting treatment means recent quarterly comparisons exclude B Medical from continuing‑operations results, affecting headline metrics such as revenue mix and adjusted operating measures. Azenta is positioning the transaction as completing its strategic repositioning begun in fiscal 2025 and expects the sale to simplify reporting going forward.

The move has near-term implications for cash flow and capital allocation, with the timing of closing set to determine when proceeds and any related gains or losses are recognized outside continuing operations. Azenta’s decision to accelerate the sale process and enter a definitive agreement signals management urgency to finalize the portfolio change in the current fiscal window, while the remaining business faces the task of offsetting the lost contribution from the divested unit.

Quarterly revenue and segment trends

For the quarter ended Dec. 31, 2025, Azenta reports revenue from continuing operations of $149.0 million, down 7% sequentially from $159.0 million and up 1% year‑over‑year from $147.0 million; organic growth is negative 1%. By segment, Sample Management Solutions brings in $81.0 million (down 5% sequentially, flat year‑over‑year) and Multiomics reports $67.0 million (down 8% sequentially, up 1% year‑over‑year).

Profitability and adjusted results

Reported diluted EPS from continuing operations is a loss of $0.11, compared with $1.12 in the prior quarter and a loss of $0.16 a year earlier; total diluted EPS is a loss of $0.34. On a non‑GAAP basis, diluted EPS from continuing operations is $0.09. Adjusted EBITDA from continuing operations is $13.0 million, down 39% sequentially and 21% year‑over‑year, reflecting pressure on margins as Azenta executes its portfolio transition.